Oncotalks | Powered by Novartis

ASCO

Interviews recorded at the American Society of Clinical Oncology congress

ASCO 2019 Prof. Axel Hauschild, MD

ASCO 2019 Prof. Axel Hauschild, MD

Prof. Axel Hauschild, MD from the University Hospital Schleswig-Holstein, Kiel is discussing "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)", which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:03:36

ASCO 2019 Juan Martin-Liberal, MD, PhD

ASCO 2019 Juan Martin-Liberal, MD, PhD

Juan Martin-Liberal, MD, PhD from Institut Català d'Oncologia, BarcelonaCommenting on: Schadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582), presented at the ASCO 2019 in Chicago

ASCO , Lithuania , Albania

00:02:06

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

Prof. Michelino DeLaurentiis, MD, PhD from the National Cancer Institute Fondazione G. Pascale is commenting on his abstract "DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)", which was presented at ASCO 2019 in Chicago

ASCO , Kisqali Channel , Lithuania , Albania , Slovenia

00:03:07

ASCO 2019 Paul Nathan, MD

ASCO 2019 Paul Nathan, MD

Paul Nathan, MD from the Mount Vernon Cancer Centre, Northwood, United Kingdom is commenting on his abstract "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)", which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Albania

00:04:09

ASCO 2019 Prof. Patrick Neven, MD, PhD

ASCO 2019 Prof. Patrick Neven, MD, PhD

Prof. Patrick Neven, MD, PhD from the UZ Leuven is commenting on his personal top 3 highlights from ASCO 2019 in Chicago1. Saura C. et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. J Clin Oncol 37, 2019 (suppl; abstr 1002)2. Schmid P. et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 37, 2019 (suppl; abstr 1003)3. Hurvitz S.A. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol 37, 2019 (suppl; abstr LBA1008)

ASCO , Lithuania , Albania

00:03:43

ASCO 2019 Prof. Dirk Schadendorf, MD

ASCO 2019 Prof. Dirk Schadendorf, MD

Prof. Dirk Schadendorf, MD from the University Hospital Essen, Germany is commenting on his abstract that was presented at ASCO 2019 in ChicagoSchadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)

ASCO , Latvia , Lithuania , Estonia , Hungary , Albania

00:10:57

ASCO 2019 Amir Sonnenblick, MD, PhD

ASCO 2019 Amir Sonnenblick, MD, PhD

Amir Sonnenblick, MD, PhD from the Tel Aviv Sourasky Medical Center commenting on "Hurvitz S.A. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol 37, 2019 (suppl; abstr LBA1008)", which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Albania

00:03:19

ASCO 2019 Prof. Gil Bar-Sela, MD

ASCO 2019 Prof. Gil Bar-Sela, MD

Prof. Gil Bar-Sela, MD from the Emek Medical center, Afula is commenting on the abstract "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)", which was presented at ASCO 2019 in Chicago

ASCO

00:07:28

ASCO 2019 Rafael Villanueva, MD

ASCO 2019 Rafael Villanueva, MD

Rafael Villanueva, MD from the Institut Català d'Oncologia, Barcelona, Spain is commenting on his abstract that has been presented at ASCO 2019 in Chicago. Hurvitz S.A. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol 37, 2019 (suppl; abstr LBA1008)

ASCO , Kisqali Channel , Lithuania , Hungary , Albania

00:04:01

1
2
»